Sensus Healthcare (NASDAQ:SRTS) Issues Earnings Results, Misses Expectations By $0.03 EPS

Sensus Healthcare (NASDAQ:SRTS) posted its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03), FiscalAI reports. The firm had revenue of $6.00 million for the quarter, compared to the consensus estimate of $6.61 million. Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%.

Sensus Healthcare Price Performance

SRTS stock traded down $0.19 during midday trading on Thursday, hitting $3.22. The stock had a trading volume of 82,587 shares, compared to its average volume of 104,935. The business has a 50-day moving average of $3.00 and a two-hundred day moving average of $3.47. The firm has a market cap of $53.00 million, a price-to-earnings ratio of -3.43 and a beta of 1.18. Sensus Healthcare has a 52-week low of $2.66 and a 52-week high of $5.49.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SRTS. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Lake Street Capital reduced their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Sensus Healthcare has an average rating of “Moderate Buy” and an average price target of $5.83.

Insider Buying and Selling

In other Sensus Healthcare news, Director Eric Sachetta acquired 37,537 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The shares were acquired at an average price of $3.44 per share, with a total value of $129,127.28. Following the completion of the purchase, the director directly owned 267,480 shares of the company’s stock, valued at approximately $920,131.20. The trade was a 16.32% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders acquired a total of 120,171 shares of company stock worth $405,230 over the last ninety days. Company insiders own 10.20% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin. Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.